Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Hafner

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
The Journal of Infectious Diseases|March 27, 2012
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the futureChristian Lienhardt, Mario Raviglione, Mel Spigelman, et al.
The Journal of Infectious Diseases|March 27, 2012
Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needsAlimuddin Zumla, Rifat Atun, Markus Maeurer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 4, 2005
The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosisDavid C Perlman, Yoninah Segal, Susan Rosenkranz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2004
The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosisDavid C Perlman, Yoninah Segal, Susan Rosenkranz, et al.
Journal of Clinical Immunology|April 12, 2005
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067Ronald D'Amico, Yijun Yang, Donna Mildvan, et al.
Clinical Pharmacology and Therapeutics|August 9, 2005
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersMarshall J Glesby, Judith A Aberg, Michelle A Kendall, et al.
American Journal of Respiratory and Critical Care Medicine|July 9, 2016
Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with TuberculosisMelissa D Chengalroyen, Germar M Beukes, Bhavna G Gordhan, et al.
The Lancet. Microbe|April 9, 2021
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trialAndreas Diacon, Sachiko Miyahara, Rodney Dawson, et al.
Annals of Internal Medicine|July 18, 2002
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDSPhilip C Johnson, L Joseph Wheat, Gretchen A Cloud, et al.
The Journal of Infectious Diseases|March 28, 2003
A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study TeamJudith A Aberg, Paige L Williams, Tun Liu, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
The Journal of Infectious Diseases|March 27, 2012
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the futureChristian Lienhardt, Mario Raviglione, Mel Spigelman, et al.
The Journal of Infectious Diseases|March 27, 2012
Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needsAlimuddin Zumla, Rifat Atun, Markus Maeurer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 4, 2005
The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosisDavid C Perlman, Yoninah Segal, Susan Rosenkranz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 7, 2004
The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosisDavid C Perlman, Yoninah Segal, Susan Rosenkranz, et al.
Journal of Clinical Immunology|April 12, 2005
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067Ronald D'Amico, Yijun Yang, Donna Mildvan, et al.
Clinical Pharmacology and Therapeutics|August 9, 2005
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersMarshall J Glesby, Judith A Aberg, Michelle A Kendall, et al.
American Journal of Respiratory and Critical Care Medicine|July 9, 2016
Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with TuberculosisMelissa D Chengalroyen, Germar M Beukes, Bhavna G Gordhan, et al.
The Lancet. Microbe|April 9, 2021
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trialAndreas Diacon, Sachiko Miyahara, Rodney Dawson, et al.
Annals of Internal Medicine|July 18, 2002
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDSPhilip C Johnson, L Joseph Wheat, Gretchen A Cloud, et al.
The Journal of Infectious Diseases|March 28, 2003
A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study TeamJudith A Aberg, Paige L Williams, Tun Liu, et al.
Pageof 5